However, using this diversity as an advantage by targeting PP2A using molecular glues and/or disruptors could allow for the specificity to re-establish PP2A homeostasis for the treatment of a broad range of cancers (20, 44, 47, 64, 194, 195, 196, 197, 198, 199). The gene discussed is PTPA; the disease is cancer.